In a report published in The Lancet Infectious Diseases (Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomized, double-blind, placebo-controlled, phase 1 and 2 trials) a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable protective efficacy against malaria shown by Sanaria® PfSPZ Vaccine when administered to women prior to pregnancy.
4DMT provides clinical programme updates for its wet AMD gene therapy – Pharmaceutical Technology
Detailed Phase II results are expected in the first half of 2024. Image Credit: Net Vector / Shutterstock. 4D Molecular Therapeutics (4DMT) has provided a
July 18, 2023